Oragenics Acquires Odyssey Health Neurological Drug Assets
January 2, 2024
Oragenics, Inc. completed the acquisition of Odyssey Health, Inc.'s neurological drug therapy assets, including ONP-002, ONP-001 rights, a proprietary intranasal delivery device and related formulations. Odyssey retained its remaining assets and operations; Michael Redmond (former Odyssey CEO) was named President of Oragenics to oversee integration and advancement of the neurology pipeline as Oragenics prepares for Phase 2 studies of ONP-002.
- Buyers
- Oragenics, Inc.
- Targets
- Odyssey Health, Inc. (neurological assets)
- Sellers
- Odyssey Health, Inc.
- Industry
- Pharmaceuticals
- Location
- Nevada, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Oragenics Acquires Noachis Terra Inc.
May 4, 2020
Biotechnology
Oragenics, Inc. has acquired Noachis Terra Inc., including a worldwide, nonexclusive NIH license for the TerraCoV2 SARS-CoV-2 vaccine candidate, in a stock purchase transaction that made Noachis Terra a wholly owned subsidiary. The deal included cash, shares and warrants and positions Oragenics to advance TerraCoV2 toward clinical development, potentially financed by company cash and government grants (NIH/BARDA).
-
Otsuka Pharmaceutical Acquires Jnana Therapeutics
August 1, 2024
Biotechnology
Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.
-
BioVie Acquires Biopharma Assets of NeurMedix
June 11, 2021
Pharmaceuticals
BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.
-
Odyssey Investment Partners Acquires ProPharma Group
September 22, 2020
Healthcare Services
Odyssey Investment Partners has agreed to acquire ProPharma Group from Linden Capital Partners. ProPharma Group, a global provider of regulatory, compliance, pharmacovigilance and medical information services headquartered in Overland Park, Kansas, will be led by CEO Dawn Sherman and the existing management team who are reinvesting alongside Odyssey to pursue organic and inorganic growth.
-
Indivior Acquires Opiant Pharmaceuticals
November 14, 2022
Pharmaceuticals
Indivior PLC will acquire Opiant Pharmaceuticals, Inc. for $20.00 per share in cash (approximately $145 million aggregate) plus up to $8.00 per share in contingent value rights tied to OPNT003 revenue milestones. The acquisition strengthens Indivior's addiction-treatment portfolio by adding Opiant's OPNT003 intranasal opioid overdose candidate and earlier-stage pipeline assets, and is expected to be accretive after the second full year of OPNT003 launch.
-
Pharmanovia Acquires Global CNS Portfolio from Sanofi
September 18, 2023
Pharmaceuticals
Pharmanovia, a Triton Fund V portfolio company, has acquired an 11‑brand global central nervous system (CNS) portfolio from Sanofi, including Frisium (clobazam) and Gardenal (phenobarbital). The asset package, available in 60+ markets, expands Pharmanovia's neurology franchise and commercial footprint across markets such as Brazil, South Africa, France and Italy in a divestiture from Sanofi.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.